# BEFORE THE LEGISLATIVE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

### REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: FRI DAY, DECEMBER 19, 2008

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 83340

# INDEX

ITEM	DESCRI PTI ON	PAGE	NO
CALL TO ORDER			3
ROLL CALL			3
HOOVER COMMISINFORMATION R	OF REQUEST FROM LITTLE SION FOR ADDITIONAL EGARDING CIRM GOVERNANCE, MENT STRUCTURE, AND OTHER		4

2

	DARRISTERS REPORTING SERVICE
1	FRI DAY, DECEMBER 19, 2008
2	3 P.M.
3	
4	CHAIRMAN KLEIN: WE'RE GOING TO START THE
5	MEETING TODAY, WHICH WE'RE GOING TO TRY AND KEEP
6	VERY SHORT. WE'RE GOING TO PLACE THIS IS BOB
7	KLEIN, AND WE WILL PLACE A NUMBER OF ITEMS INTO A
8	STUDY MODE FOR REASONS THAT I'LL OUTLINE DURING THIS
9	DISCUSSION. I THINK THE LEGISLATION AT THE FEDERAL
10	LEVEL IS GOING TO GO MUCH QUICKER POTENTIALLY IN
11	SOME AREAS THAN WE HAD EXPECTED.
12	SO I'M GOING TO ASK IF MELISSA KING WOULD
13	CALL THE ROLL SO WE CAN SEE THE SITES THAT ARE ON
14	BOARD.
15	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
16	DR. LEVIN: HERE.
17	MS. KING: MICHAEL GOLDBERG.
18	MR. GOLDBERG: HERE.
19	MS. KING: BOB KLEIN.
20	CHAIRMAN KLEIN: HERE.
21	MS. KING: SHERRY LANSING. CLAIRE
22	POMEROY.
23	DR. POMEROY: HERE.
24	MS. KING: FRANCISCO PRIETO.
25	DR. PRI ETO: HERE.
	3
	3

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. KING: JEANNIE FONTANA FOR JOHN REED.
2	JOAN SAMUELSON. JEFF SHEEHY.
3	MR. SHEEHY: HERE.
4	CHAIRMAN KLEIN: OKAY.
5	MS. KING: JUST FOR THE RECORD, WE DO HAVE
6	A QUORUM.
7	CHAIRMAN KLEIN: ALL RIGHT. FOR CONTEXT,
8	WE'RE GOING TO DISCUSS TWO CATEGORIES OF INFORMATION
9	TODAY. ONE TO START A PROCESS OF COMING UP WITH
10	POTENTIAL SUGGESTIONS FOR THE LITTLE HOOVER
11	COMMISSION AND, NO. 2, TO ADDRESS FEDERAL
12	LEGISLATIVE OPPORTUNITIES IN PLACING A TIMEFRAME
13	AROUND THESE TWO SUBJECTS.
14	I'D LIKE TO SAY THAT THE LATEST AND
15	PENDING INFORMATION INDICATES THAT CONGRESS MAY TRY
16	AND PASS A GROUP OF LEGISLATIVE INITIATIVES PRIOR TO
17	THE PRESIDENT'S INAUGURATION, SO IMMEDIATELY UPON
18	STEPPING INTO OFFICE, HE COULD SIGN THOSE. THAT'S
19	NOT BEEN FULLY DETERMINED, BUT IT IS CERTAINLY ONE
20	OF THE PROPOSALS THAT'S PENDING THAT WE HAVE TO TAKE
21	INTO ACCOUNT.
22	STARTING WITH THE LEGISLATIVE OPPORTUNITY
23	AREA, THE EMBRYONIC STEM CELL BILL, THE
24	CASTLE-DEGETTE BILL AND ITS COMPANION IN THE SENATE,
25	WHICH WILL NOW BE RENAMED WITH THE DEMOCRATIC NAMES
	4

ı	AT THE BEGINNING, ARE GOING TO BE BROUGHT UP.
2	SPEAKER PELOSI HAS INDICATED SHE'LL BRING THE BILL
3	UP AS ONE OF HER TOP FIVE. THERE ARE, OF COURSE, A
4	NUMBER OF EXTRAORDINARILY IMPORTANT INITIATIVES
5	PENDING, SO THE FINAL ORDER OF WHAT'S BROUGHT UP IS
6	CONSTANTLY SUBJECT TO CHANGE.
7	BUT WE PREVIOUSLY ENDORSED THE EMBRYONIC
8	STEM CELL BILLS INITIATED BY THE LEADERSHIP IN BOTH
9	HOUSES THAT WERE VETOED LAST YEAR. AS A MATTER OF
10	PROCESS, WE SHOULD, HOWEVER, JUST CONSIDER A FORMAL
11	MOTION, IF IT'S APPROPRIATE, AND THEN TO BE
12	DISCUSSED, TO SUPPORT THOSE BILLS THIS YEAR.
13	PARTICULARLY BECAUSE THE BOARD MEETING WILL
14	POTENTIALLY COME AFTER WHAT WE NEED TO TAKE SOME
15	ADVI SORY ACTION.
16	BECAUSE WE'VE PREVIOUSLY APPROVED THESE
17	BILLS AT THE BOARD LEVEL, I JUST WANT TO MAKE
18	CERTAIN THAT THERE'S BEEN NO CHANGE THAT ANY OF THE
19	MEMBERS OF THIS COMMITTEE ARE AWARE OF. AND WE MAY,
20	IF NECESSARY, ON OTHER ACTIONS CALL A TELEPHONIC
21	BOARD MEETING BEFORE OUR BOARD MEETING AT THE END OF
22	JANUARY IF, IN FACT, WE HAVE CONFIRMED THAT
23	CONGRESSIONAL ACTION IS ANTICIPATED ON SEVERAL OTHER
24	BILLS THAT MAY BE MUCH MORE COMPLEX AND NEW TO US IN
25	TERMS OF SUBJECT AND SCOPE.

1	BUT IS THERE A MOTION TO RENEW AND EXTEND
2	OUR APPROVAL OF THE SPECIFIC BILL HERE? AND I WILL
3	AGAIN ASK DID YOU GET THROUGH THE WHOLE LIST,
4	MELI SSA?
5	MS. KING: I DID GET THROUGH THE WHOLE
6	LIST, AND WE HAVE A QUORUM.
7	DR. PRIETO: I'LL SO MOVE.
8	CHAIRMAN KLEIN: WE CAN DO JAMES IS
9	INDICATING THAT SINCE WE DIDN'T SPECIFICALLY
10	AGENDIZE THAT ITEM, IT'S REALLY A STRAW VOTE, NOT A
11	FORMAL IT'S NOT GOING TO HAVE THE SAME IMPACT AS
12	A FORMAL RESOLUTION.
13	DR. PRIETO: SENSE OF THE COMMITTEE.
14	CHAIRMAN KLEIN: SENSE OF THE COMMITTEE.
15	SO, FRANCISCO, YOU PUT IT ON THE TABLE. IS THERE
16	ESSENTIALLY AN INFORMAL SECOND ON THAT?
17	DR. POMEROY: INFORMALLY SECONDED.
18	CHAIRMAN KLEIN: OKAY. THANK YOU.
19	DI SCUSSI ON?
20	DR. PRIETO: HOPE THIS HAPPENS SOON.
21	CHAIRMAN KLEIN: I DON'T THINK THERE'S
22	ANYTHING SUBSTANTIVELY TO ADD TO THIS. IF THE BILL
23	IS PUBLISHED IN A DIFFERENT FORM THAT GOES A GREAT
24	DEAL FURTHER THAN THE PRIOR BILL, WE'RE GOING TO
25	BRING THIS BACK. SO IT IS VERY IMPORTANT TO REALIZE

1	THAT THESE BILLS MAY CHANGE SUBSTANTIALLY FROM LAST
2	YEAR. AND IF THEY DO, THEY'RE GOING TO COME BACK
3	HERE.
4	OKAY. I DON'T THINK THERE'S ANYTHING
5	CONTROVERSIAL ABOUT THIS, BUT ANY PUBLIC COMMENT?
6	MS. KING: NOT HERE IN SAN FRANCISCO. ANY
7	PUBLIC COMMENT AT ANY OF THE OTHER SITES?
8	DR. PRI ETO: NOT HERE.
9	DR. POMEROY: NO COMMENTS.
10	CHAIRMAN KLEIN: OKAY. ALL RIGHT. SO
11	WE'RE GOING TO JUST ASK IS THERE, SINCE WE'RE
12	THIS IS NOT A FORMAL MOTION. WE REALLY DON'T NEED
13	TO GO THROUGH A ROLL CALL VOTE. BUT IS THERE
14	CONSENT ON THE COMMITTEE AS THE SENSE OF THE
15	COMMITTEE, IF YOU WILL PLEASE SAY YES.
16	(ALL MEMBERS ON THE CALL RESPOND
17	YES.)
18	CHAIRMAN KLEIN: ANY OPPOSITION? THANK
19	YOU. SO WE'RE GOING TO TRY AND GET, AS SOON AS
20	SOMETHING IS IN PRINT, DISTRIBUTION TO ALL THE
21	MEMBERS ON THAT.
22	NOW, IN PREPARATION FOR DISCUSSION AT THE
23	JANUARY BOARD MEETING, I ASKED DR. SUSAN BRYANT TO
24	IDENTIFY SPEAKERS ON THE NIH BUDGET AND THE CRITICAL
25	NEED TO INCREASE THAT BUDGET. IS THERE ANYONE ELSE
	7

1	WHO WOULD LIKE TO VOLUNTEER TO HELP IDENTIFY ONE OR
2	TWO EXPERT SPEAKERS WHO CAN SPEAK TO THE BOARD ON
3	THE 29TH OR THE 30TH OF JANUARY ON THE CRITICAL NEED
4	TO INCREASE THE NIH BUDGET? HEARING NO ADDITIONAL
5	VOLUNTEERS, JACOB, ARE YOU ON?
6	DR. LEVIN: YES, I AM.
7	CHAIRMAN KLEIN: JACOB LEVIN IS ON FOR
8	SUSAN BRYANT. SO SUSAN HAS THE POINT POSITION ON
9	THIS, BUT I WILL BACKSTOP THAT, JACOB.
10	ON THE ISSUE OF FDA STAFFING, IN THIS CASE
11	AS WELL AS THE NIH, IF WE HAVE ANOTHER MEETING
12	BEFORE OUR BOARD MEETING IN JANUARY AND HAVE A BILL
13	IN PRINT, WE'RE GOING TO HAVE THE BILL IN FRONT OF
14	US. THAT WOULD OBVIOUSLY SUBSTANTIALLY HELP OUR
15	DI SCUSSI ON.
16	IN ADDITION, FROM THE ADMINISTRATION SIDE,
17	THERE'S BEEN A DISCUSSION OF PLACING SOME NIH
18	FUNDING FOR MEDICAL RESEARCH IN THE STIMULUS
19	PACKAGE. WE DON'T KNOW IF THAT'S GOING TO OCCUR
20	YET; BUT IF THE STIMULUS PACKAGE IN DRAFT IS
21	AVAILABLE, WE WILL ALSO DISTRIBUTE THAT.
22	ANOTHER ISSUE OF SIGNIFICANT IMPORTANCE
23	THAT WE HAVE PREVIOUSLY BROUGHT UP FOR THE BOARD IN
24	THE MIDST OF OTHER DISCUSSIONS, BUT NOT AS
25	SIGNIFICANT FOCUS, IS INCREASING THE FDA FUNDING.

1	DR. FRIEDMAN HAS VOLUNTEERED TO IDENTIFY INDIVIDUALS
2	WHO CAN SPEAK TO THE BOARD ON JANUARY THE 29TH ON
3	FDA STAFFING. IS THERE ANYONE ELSE WHO WOULD HELP
4	DR. FRIEDMAN ON FDA STAFFING? IS THERE ANYONE ELSE
5	WHO WOULD VOLUNTEER TO HELP IDENTIFY ADDITIONAL
6	EXPERTS ON FDA STAFFING NEEDS? ALL RIGHT. DR.
7	FRIEDMAN HAS RESPONSIBILITY, FAIRLY FOCUSED, AND
8	OBVIOUSLY, AS A FORMER FDA COMMISSIONER, HE'S GOT
9	TREMENDOUS CONTACTS IN THAT AREA.
10	IN TERMS OF FDA STAFFING, DOES ANY BOARD
11	MEMBER OR ANY MEMBER OF THE PUBLIC AT THIS TIME WANT
12	TO DISCUSS ANY ELEMENTS OF THAT THEY WOULD LIKE TO
13	SEE DISCUSSED AT THE JANUARY BOARD MEETING? OKAY.
14	NO SPECIFIC FOCUS.
15	LET ME DESCRIBE TWO OTHER AREAS THAT HAVE
16	BEEN BROUGHT UP ONLY IN BASIC REFERENCES IN THE
17	PRIOR BOARD MEETINGS. ONE IS ON OUR LOAN PROGRAM.
18	CURRENTLY WE HAVE A PRICE WATERHOUSE ANALYSIS THAT
19	ANTICIPATES THAT EVEN WITH A VERY HIGH
20	NONPERFORMANCE RATE ON THE LOAN PROGRAMS WE PUT OUT
21	THERE, THAT IN OVER A SEVEN- TO TEN-YEAR CYCLE FOR
22	THOSE LOANS THAT DO PAY, WE SHOULD FROM PRINCIPAL,
23	INTEREST, AND FROM STOCK WARRANT REVENUE GAIN ENOUGH
24	REVENUE TO, IN FACT, RETURN OUR CAPITAL AND HAVE
25	ABOUT A 20-PERCENT GROWTH IN OUR FUND.

1	NOW, IN FACT, RIGHT NOW WE'RE FUNDING A
2	HUNDRED PERCENT OF THESE LOANS. SO WE'RE IN A
3	POSITION THAT IF THESE LOANS DON'T REACH THAT
4	PERFORMANCE LEVEL, IF WE GOT BACK HALF OF OUR
5	CAPITAL, WE WOULD BE 50 PERCENT AHEAD OF WHERE WE
6	WOULD BE ON GRANTS BECAUSE AT LEAST WE'D HAVE THAT
7	PORTION OF OUR PORTFOLIO THAT WE WOULD HAVE
8	RECOVERED TO READVANCE AS LOANS.
9	WITH THE BROAD USE OF LOAN GUARANTEES AT
10	THE FEDERAL LEVEL FOR A NUMBER OF INDUSTRIES,
11	HOWEVER, THERE IS A POTENTIAL THAT WITHIN THE
12	ADMINISTRATION'S PACKAGE OR WITHIN THE CONGRESSIONAL
13	PACKAGE THAT LOAN GUARANTEES OF STATE OR GOVERNMENT
14	ENTITIES FOR MEDICAL SCIENTIFIC RESEARCH COULD BE
15	INCLUDED. THE LINE OF LEAST RESISTANCE WOULD BE TO
16	HAVE THE FEDERAL GOVERNMENT GUARANTEE THE BOTTOM 50
17	PERCENT OF ANY LOAN PORTFOLIO BECAUSE AT THAT POINT
18	THEY'D BE IN A MUCH BETTER POSITION THAN THEY WOULD
19	HAVE BEEN IN WITH THE OTHER LOAN PROGRAMS WHERE
20	THEY'RE COMING IN WITH THE TOP PERCENTAGE OF THE
21	LOAN GUARANTEED.
22	DR. PRIETO: BOB, COULD YOU DEFINE WHAT
23	YOU MEAN BY THAT, BY BOTTOM AND TOP OF THE LOAN
24	PORTFOLI 0?
25	CHAIRMAN KLEIN: SURE. IF YOU HAVE A LOAN
	10

1	FOR \$20 MILLION UNDER DISEASE TEAMS, IF THE FEDERAL
2	GOVERNMENT WERE PREPARED TO COME IN WITH A BOTTOM 50
3	PERCENT GUARANTEE, THAT MEANS THAT ON THAT LOAN THEY
4	WOULD GUARANTEE THE BOTTOM 10 MILLION OF THAT \$20
5	MILLION LOAN. ON TAKING THAT TO THE PORTFOLIO
6	LEVEL, IF WE WERE PREPARED TO ADVANCE \$500 MILLION
7	OF LOANS, THAT COULD BE CONSIDERED THE TOP 50
8	PERCENT OF A BILLION-DOLLAR PORTFOLIO. SO IF THE
9	FEDERAL GOVERNMENT WERE TO GUARANTEE THE BOTTOM 50
10	PERCENT OF THAT PORTFOLIO, IT MEANS THAT IF WE
11	ORIGINATE A BILLION DOLLARS WORTH OF LOANS, AND WE
12	GET \$600 MILLION IN PAYBACK, ACCORDING TO THE PRICE
13	WATERHOUSE PROJECTIONS, THAT WE ESSENTIALLY WOULD
14	TAKE THE TOP LOSS, WHICH WOULD MEAN WE WOULD TAKE
15	\$400 MILLION OF LOSS, WE'D GET BACK A HUNDRED
16	MILLION, AND THE FEDERAL GOVERNMENT WOULD NOT HAVE
17	SUFFERED A LOSS. ALL RIGHT.
18	DR. PRIETO: SO THEY WOULD BE LIKE THE
19	FIRST CREDITOR.
20	CHAIRMAN KLEIN: THEY WOULD BE A SUPERIOR
21	CREDITOR. THAT'S RIGHT.
22	DR. PRI ETO: OKAY.
23	CHAIRMAN KLEIN: NOW, THE KEY HERE IS THAT
24	WHAT IT DOES FOR US IS IT ALLOWS US TO SUBSTANTIALLY
25	ENHANCE THE VOLUME OF OUR LOAN PROGRAM. AND DURING

1	THIS PARTICULAR TIME PERIOD WE'RE IN, IF WE HAD LOAN
2	GUARANTEES, IT COULD SIGNIFICANTLY INCREASE THE
3	FUNDS WE HAD AVAILABLE FOR FUNDING TO OUR GRANTEE
4	INSTITUTIONS. SO, FOR EXAMPLE, LET US SAY THAT WE
5	NEEDED \$300 MILLION FOR FISCAL YEAR '09-'10, BUT
6	BECAUSE OF CREDIT RATIONING, WE COULD ONLY GET \$200
7	MILLION. IF THE LOAN PROGRAM GUARANTEES WERE IN
8	PLACE AND WE DID A HUNDRED MILLION, WE WERE ABLE TO
9	PUT UP A HUNDRED MILLION OF OUR 200 MILLION INTO A
10	LOAN PROGRAM, THE FEDERAL GUARANTEES WOULD MEAN THAT
11	WE COULD RAISE ANOTHER HUNDRED MILLION BECAUSE OF
12	FEDERAL GUARANTEES THROUGH PRIVATE BANKING
13	INSTITUTIONS, WHO WOULD, IN FACT, PICK UP THE BOTTOM
14	50 PERCENT BECAUSE THEY WOULD NOT HAVE A LOSS
15	EXPOSURE ON IT.
16	NOW, OBVIOUSLY WE COULD NEGOTIATE THE
17	ALLOCATION OF THAT 500 MILLION OF THAT LOAN
18	GUARANTEE BY THE FEDERAL GOVERNMENT SO THAT THE
19	INSTITUTIONS MIGHT HAVE 95 PERCENT OF THEIR MONEY
20	COVERED BY THE FEDERAL GUARANTEE AND A 5-PERCENT
21	EXPOSURE. BUT IN A SIMPLISTIC VIEWPOINT, HAVING A
22	LOAN GUARANTEE PROGRAM IN PLACE EFFECTIVELY MEANS
23	THAT WHATEVER WE PUT OUT IN LOANS, WE CAN DOUBLE
24	THAT AMOUNT IN OUR PROGRAM APPROVALS. SO ONLY IF WE
25	CAN ONLY GET 200 MILLION FROM THE BOND MARKET, THAT

1	OTHER HUNDRED MILLION MEANS WE CAN HAVE A \$300
2	MILLION PROGRAM IN THAT YEAR. ALL RIGHT.
3	DR. PRI ETO: OKAY.
4	CHAIRMAN KLEIN: IS THERE ANYONE WHO WOULD
5	BE WILLING TO WORK ON THIS PARTICULAR ITEM IN
6	ADDITION TO THE TIME THAT I SPEND ON IT? NOT AN
7	AREA THAT EVERYONE DEALS WITH EVERY DAY.
8	DR. PRI ETO: NO.
9	MS. KING: I WAS GOING TO SAY YOU MIGHT
10	JUST WANT TO DESCRIBE IN A LITTLE BIT MORE DETAIL TO
11	THE MEMBERS WHAT THAT MIGHT INVOLVE.
12	CHAIRMAN KLEIN: WELL, OBVIOUSLY THIS IS
13	CHANGING DAILY IN TERMS OF WASHINGTON, D.C., BOTH IN
14	THE ADMINISTRATION SIDE AND IN TERMS OF THE
15	CONGRESSIONAL SIDE WITH HUNDREDS OF BILLIONS OF
16	DOLLARS IN PROPOSALS THAT HAVE BEEN PUT INTO A
17	PRIORITY POSITION AND HUNDREDS OF BILLIONS OF
18	DOLLARS OF PROPOSALS THAT ARE ESSENTIALLY IN FLUX.
19	SO ESSENTIALLY THAT ADDITIONAL PERSON
20	WOULD ACT AS A SOUNDING BOARD IN TERMS OF THE
21	POTENTIAL OPPORTUNITIES WE MIGHT HAVE AND STRUCTURES
22	WE MIGHT HAVE IN CARRYING OUT SOME LOAN GUARANTEE
23	PROGRAM WITH THE FEDERAL GOVERNMENT.
24	OF THE PEOPLE ON THE LINE, MICHAEL
25	GOLDBERG, ARE YOU THERE?
	40

1	MS. KING: HE'S THERE. HE MAY HAVE MUTED.
2	MR. GOLDBERG: I'M HERE.
3	CHAIRMAN KLEIN: OKAY. MICHAEL, YOUR
4	SPECIFIC BACKGROUND IS PROBABLY THE MOST APPROPRIATE
5	FOR THIS AREA.
6	MR. GOLDBERG: WELL, I WAS ON MUTE, BUT I
7	VOLUNTEERED. SORRY. I DIDN'T KNOW.
8	CHAIRMAN KLEIN: OKAY. GREAT. SO,
9	MICHAEL, THAT WOULD BE GREAT IF YOU WOULD WORK ON
10	THAT AREA. AS CHAIR OF THE FINANCE SUBCOMMITTEE,
11	IT'S PROBABLY PARTICULARLY APPROPRIATE TO HAVE YOU
12	WORKING ON THIS.
13	THE OTHER AREA OF INNOVATIVE POLICY THAT
14	IS UNDER CONSIDERATION IS A MODIFICATION OF THE
15	EXISTING R & D TAX CREDIT RULES. THIS PARTICULAR
16	IDEA I PUT INTO THE INNOVATIVE, BUT NOT HIGHLY
17	PROBABLE OUTCOME RANGE BECAUSE THERE ARE MAJOR
18	PLAYERS ON THE OPPOSITION SIDE WHO MIGHT OPPOSE IT
19	OR WOULD PREDICTABLY OPPOSE IT.
20	BUT SPECIFICALLY IN THE R & D TAX CREDIT
21	AREA RIGHT NOW, IT'S MAJOR PHARMA AND MAJOR, VERY
22	LARGE-SCALE BIOTECH WHO HAVE THE PROFITS THAT CAN
23	USE IT. BUT GIVEN WE HAVE A BIOTECH CREDIT CRISIS
24	NOW DEALING WITH SMALL COMPANIES AND A SCARCITY OF
25	FUNDS FOR THE RESEARCH COMMUNITY TO BRING THERAPY

1	DEVELOPMENT THROUGH PHASE I AND PHASE II OR II A AND
2	II B TRIALS, WE HAVE A MISALIGNMENT OF WHERE THE
3	CREDIT SCARCITY IS WITH WHERE THE SUBSIDIES ARE
4	GOING INTO THE SYSTEM.
5	SO THERE'S EXISTING LARGE-SCALE R & D TAX
6	CREDIT SUBSIDIES THAT MAJOR PHARMA IS USING THOSE
7	DOLLARS WITHOUT INCREASING THE ALLOCATION TO THAT
8	USE. IF THEY WERE DECOUPLED FROM THE ENTITY THAT
9	IF THE TAX BENEFITS WERE DECOUPLED FROM THE ENTITY
10	THAT DOES THE EXPENDITURE, WE COULD HAVE THE
11	OPPORTUNITY FOR SMALL BIOTECH COMPANIES WHO CANNOT
12	USE THE TAX CREDIT TO SELL THOSE R & D TAX CREDITS.
13	SO, FOR EXAMPLE, IN OUR DISEASE TEAMS,
14	THIS COULD BE A SUBSTANTIAL SUPPLEMENTAL FUNDING
15	SOURCE BECAUSE THE EXPENDITURES MADE THERE COULD
16	QUALIFY THEM FOR SIGNIFICANT R & D TAX CREDITS WHICH
17	COULD BE SOLD, PROVIDING ANOTHER SOURCE OF CAPITAL.
18	DR. PRIETO: CAN I ASK A QUESTION ABOUT
19	THAT, BOB? I'M NOT SURE I'M CLEAR WHO THEY WOULD
20	SELL THOSE TO AND HOW THE BUYER I GATHER I
21	THINK I UNDERSTAND THAT THEY WOULDN'T BE ABLE TO USE
22	THE TAX CREDITS BECAUSE THEY DON'T HAVE THE PROFITS
23	TO PAY TAXES ON, BUT HOW WOULD THE BUYER BENEFIT?
24	CHAIRMAN KLEIN: SO LET'S TAKE BY ANALOGY
25	THE AFFORDABLE HOUSING AREA WHERE FOR EVEN NONPROFIT

1	ORGANIZATIONS WHO DEVELOP AFFORDABLE HOUSING
2	PROPERTIES, THEY QUALIFY FOR TAX CREDITS AS A
3	FEDERAL SUBSIDY. THEY THEN SELL THOSE CREDITS TO
4	COMPANIES WHO NEED THE TAX CREDITS ON THE OPEN
5	NATIONAL CORPORATE MARKET, AND THEY TAKE THE FUNDS
6	AND USE IT AS ONE OF THEIR PRINCIPAL FUNDING
7	RESOURCES FOR THAT AFFORDABLE HOUSING PROJECT.
8	DR. PRIETO: DID THEY SELL THEM AT A
9	DISCOUNT? IS THAT HOW IT WORKS SO THAT YOU GET A
10	DOLLAR'S WORTH OF TAX CREDIT FOR 80 CENTS OR
11	SOMETHING LIKE THAT?
12	CHAIRMAN KLEIN: WHAT THEY DO IS THEY SELL
13	THEM EFFECTIVELY FOR A DISCOUNT TO PAR, BUT WHAT
14	THEY ALSO DO IS THE PURCHASERS OF THEM AT TIMES WILL
15	PICK UP A SMALL RESIDUAL INTEREST IN THE FUTURE
16	PROJECT.
17	DR. PRIETO: OKAY. A LITTLE IP INTEREST
18	OR STOCK IN THE COMPANY?
19	CHAIRMAN KLEIN: IN OUR CASE THE MODEL
20	WOULD PERMIT A SMALL IP INTEREST IF ANY IP WERE
21	PRODUCED. BUT ESSENTIALLY THESE WHEN THE MARKET
22	WAS EFFICIENT, THESE TAX CREDITS WERE BEING SOLD,
23	TAKING THE TAX BENEFITS OVER A NUMBER OF YEARS AND
24	DISCOUNTING THEM AT AN 8-PERCENT DISCOUNT RATE, 8-
25	TO 10-PERCENT DISCOUNT RATE. SO BASICALLY IF A

1	COMPANY COULD GO OUT AND BORROW MONEY AT 4 PERCENT
2	AND THEY BUY THEM WITH TAX CREDITS DISCOUNTED AT AN
3	8-PERCENT RATE OR A 10-PERCENT RATE, THEY WOULD PICK
4	UP THE DIFFERENTIAL BETWEEN THOSE TWO RATES.
5	NOW, THE ISSCR IS GOING TO SPECIFICALLY
6	LOOK AT THE R & D TAX CREDITS AND THIS DECOUPLING.
7	BETH SIDENBERG, WHO IS WITH KLEINER PERKINS,
8	CONSULTED ALREADY WITH THEIR OUTSIDE TAX ATTORNEYS.
9	AND THIS IS SOMETHING THAT SHE REPORTS HAS
10	PREVIOUSLY BEEN DONE IN CANADA. SO THE HOPE IS THAT
11	IN REAL-TIME HERE WE'LL PICK UP FROM THEM SOME OF
12	THIS INFORMATION. BUT WHEN I INITIALLY RAISED THIS
13	IDEA TO SEE WHAT INTEREST THEY WOULD HAVE IN THIS,
14	WITHOUT TAKING ANY POSITION, JUST PUTTING IT ON THE
15	TABLE AS A WAY TO GET MORE CAPITAL INTO THIS SECTOR
16	AT A TIME WHEN WE HAVE A CAPITAL SCARCITY AND
17	PARTICULARLY WHEN STEM CELL THERAPIES AS A NEW
18	THERAPY DEVELOPMENT TYPE ARE IN A CLASS CONSIDERED
19	TO BE HIGH RISK, AND IT WAS VERY DIFFICULT TO FIND
20	CAPITAL, THIS IS JUST ANOTHER TOOL.
21	WHAT WE WOULD NEED IS FEDERAL LEGISLATION
22	TO BROADEN THE SCOPE. YOU CAN EXPECT THAT PHARMA
23	AND BIG BIOTECH COMPANIES WILL OPPOSE THIS BECAUSE
24	RIGHT NOW THEY HAVE A RELATIVE LOCK ON THIS MARKET.
25	SO THIS IS

1	DR. LEVIN: SMALL COMPANIES CAN ALSO DO
2	IT.
3	CHAIRMAN KLEIN: WHAT'S THAT?
4	DR. LEVIN: I DON'T SEE HOW IT WOULD HURT
5	PHARMA AND LARGE BIOTECH IF THE SMALL COMPANIES CAN
6	ALSO GET THE R & D TAX CREDIT.
7	CHAIRMAN KLEIN: BECAUSE THERE'S A MAXIMUM
8	DOLLAR ALLOCATION TO THIS PROGRAM.
9	MS. KING: COULD THE PERSON ASKING THAT
10	QUESTION JUST FOR THE RECORD, STATE YOUR NAME,
11	PLEASE?
12	CHAIRMAN KLEIN: WHO JUST SPOKE?
13	DR. LEVIN: JACOB FROM UCI.
14	CHAIRMAN KLEIN: SO THIS IS AN EXPLORATORY
15	ITEM AT THIS POINT TO TRY AND FIND ADDITIONAL TOOLS
16	TO DEAL WITH THIS CREDIT CRISIS PERIOD WE'RE IN.
17	AND, MICHAEL GOLDBERG, SINCE THIS IS ANOTHER STRICT
18	FINANCE ITEM, MAYBE I COULD RECRUIT YOU TO WORK ON
19	THIS ONE AS WELL?
20	MR. GOLDBERG: SURE.
21	CHAIRMAN KLEIN: IS THERE ANYONE ELSE THAT
22	WOULD BE WILLING TO WORK ON THIS ITEM?
23	MR. SHEEHY: I WOULD BE, BUT I GUESS I
24	DON'T UNDERSTAND WHAT KIND OF PROCESS WE WOULD BE
25	INITIATING. THIS SOUNDS LIKE WE'D BE LOBBYING
	18
	i U

1	SPECIFIC LEGISLATORS?
2	CHAIRMAN KLEIN: THE FIRST PHASE OF THIS
3	IS INVESTIGATION. OKAY. THEN WE COME BACK TO THIS
4	COMMITTEE AND REPORT ON THE FEASIBILITY, BUT
5	ESSENTIALLY THIS IS SIMILAR TO TAKING A POSITION ON
6	THE EMBRYONIC STEM CELL BILL IN THAT WE WOULD BE
7	TAKING A POSITION ON LEGISLATION OR ON AN
8	ADMINISTRATION PROGRAM THAT WOULD INCLUDE THIS AS AN
9	ELEMENT THAT WOULD PROVIDE MORE LIQUIDITY FOR THE
10	BIOTECH SECTOR.
11	MR. SHEEHY: IS THERE SOMEONE CARRYING
12	LEGISLATION TO DO THIS OR IN THE EARLY STAGES OF
13	PREPARING LEGISLATION FOR THIS?
14	CHAIRMAN KLEIN: NO, THERE ISN'T. I
15	TALKED TO THE CHAIRMAN OF THE U.S. SENATE FINANCE
16	COMMITTEE ABOUT BOTH IDEAS TO ASK HIM WHETHER THERE
17	WAS ANY LEGISLATION ON EITHER OF THESE, THE LOAN
18	GUARANTEE OR THE R & D TAX CREDIT. HE'S VERY
19	INTERESTED IN IT. WE WANTS TO HAVE HIS STAFF WORK
20	WITH US ON IT, BUT THERE'S NOTHING PENDING.
21	SO THESE ARE IDEAS THAT WE WOULD BE
22	INTRODUCING FOR INVESTIGATION AT THIS POINT, NOT FOR
23	ACTION, BECAUSE WE HAVE TO INVESTIGATE WHAT THE
24	POTENTIAL IS AND REPORT BACK TO THIS COMMITTEE AND
25	THE BOARD FOR AUTHORIZATION TO TAKE A POSITION.
	10

1	MR. SHEEHY: I'M WILLING TO HELP OUT.
2	CHAIRMAN KLEIN: OKAY. THAT WOULD BE
3	GREAT. THAT WOULD BE GREAT.
4	SO WHERE WE ARE HERE IS WE'RE IN A VERY
5	FAST-MOVING PERIOD WITH BOTH THE ADMINISTRATION AND
6	THE CONGRESS. AND BY HAVING INDIVIDUALS THAT CAN
7	PARTICIPATE IN THIS, WE'RE GOING TO CERTAINLY GET
8	FURTHER DOWNSTREAM MUCH FASTER AND BE ABLE TO REPORT
9	ON ACTION TO THIS COMMITTEE. THERE IS NO SPECIFIC
10	ACTION THAT IS ANTICIPATED AT THIS POINT OTHER THAN
11	JUST INITIATING THE INVESTIGATIVE STAGE EFFORTS.
12	IS THERE ANY MEMBER OF THE PUBLIC OR ANY
13	MEMBER OF THE BOARD WHO'D LIKE TO TALK OR INTRODUCE
14	ANY ITEM FOR FOCUS ON FEDERAL LEGISLATION FOR THIS
15	BOARD TO CONSIDER BEFORE WE GO ON TO THE AGENDIZED
16	ITEM THAT DEALS WITH THE LITTLE HOOVER COMMISSION?
17	DR. LEVIN: I GUESS I HAVE A QUESTION. IS
18	THERE GOING TO BE SOME SORT OF DISCUSSION OF
19	MODIFICATION OF THE STRATEGIC PLAN BASED ON ANY SORT
20	OF STEM CELL BILL THAT'S PASSING FEDERALLY? IS THAT
21	ONGOING, OR IS THERE A PLAN FOR THE ICOC AS A WHOLE
22	TO DI SCUSS THAT?
23	CHAIRMAN KLEIN: THE ICOC AT THE NEXT
24	MEETING, AS I UNDERSTOOD THE OUTCOME OF THE PRIOR
25	MEETING, IS GOING TO CONSIDER A PROCESS FOR
	20

1	DEVELOPING THAT PLAN. I THINK THERE WAS A LOT OF
2	INPUT FROM THE BOARD TO THE STAFF, AND HOPEFULLY
3	THEY'LL COME BACK WITH A PLAN OR ALTERNATIVE PLAN
4	THAT IS RESPONSIVE TO THE BOARD INPUT.
5	DR. LEVIN: SPECIFICALLY I'M THINKING OF
6	CHANGES FEDERALLY THAT IT SOUNDS LIKE YOU THINK WE
7	MIGHT LEARN ABOUT BEFORE JANUARY.
8	CHAIRMAN KLEIN: THE FEDERAL LEGISLATIVE
9	INITIATIVES MAY, IN FACT, CREATE SOME OPPORTUNITIES
10	THAT ARE NOT THERE AT THAT TIME. AND I CAN
11	CERTAINLY PASS ON A MESSAGE THAT IF THERE ARE ANY
12	STRATEGIC OPPORTUNITIES THAT ARE OPENED UP BECAUSE
13	OF FUNDING THAT IS SHORT-TERM DIRECTED, THAT THE
14	STAFF SHOULD COME BACK WITH A REPORT TO THE BOARD AT
15	THE JANUARY MEETING.
16	BUT IF YOU CAN IDENTIFY ANY OF THOSE
17	OPPORTUNITIES, THAT WOULD BE OBVIOUSLY VERY HELPFUL.
18	JACOB, THE BOARD MIGHT, DEPENDING UPON
19	WHAT'S APPROPRIATE, MIGHT BRING THE STAFF MIGHT
20	COME BACK AND SUGGEST USING SOME OF THE SPECIAL
21	FUNDS ACCESS TO BROADEN THE EXISTING PROPOSED RFA'S,
22	OR IT MAY FIT INTO A LONGER TERM BASIS WHERE IT
23	WOULD THEN BE INTEGRATED INTO THE DISCUSSION OF THE
24	STRATEGIC PLAN.
25	IN SAN FRANCISCO WE HAVE A PUBLIC COMMENT.
	21

1	BEFORE WE GET TO SAN FRANCISCO, IS THERE PUBLIC
2	COMMENT ANYWHERE ELSE?
3	DR. PRI ETO: NOT HERE.
4	CHAIRMAN KLEIN: IN SAN FRANCISCO, DON
5	REED.
6	MR. REED: AT AN EARLIER MEETING WE
7	MENTIONED THE POSSIBILITY THAT THE DICKEY-WICKER
8	AMENDMENT MIGHT BE EITHER DISPENSED WITH, NOT TACKED
9	ONTO ANY FURTHER BILLS, OR THAT IT MIGHT BE ALTERED
10	SO THAT IT WOULD NOT BE HARMFUL; FOR INSTANCE, THE
11	SCNT LANGUAGE SHOULD BE MODIFIED. YOU MENTIONED THE
12	POSSIBILITY FOR THE FEDERAL DISCUSSION.
13	CHAIRMAN KLEIN: BECAUSE THE DICKEY-WICKER
14	AMENDMENT WOULD REQUIRE A HIGHLY CONTENTIOUS CLOTURE
15	VOTE IN THE SENATE, I DON'T BELIEVE THAT IT'S CLEAR
16	WHETHER THAT'S GOING TO BE BROUGHT UP AT THE
17	BEGINNING OF THE SESSION. IT MAY BE A LATER ITEM.
18	I'M NOT AWARE IT'S GOING TO BE BROUGHT UP AT THIS
19	TIME AT THE BEGINNING OF THE SESSION. SO TRYING TO
20	FOCUS FOR THE MOMENT ON WHAT APPEARS TO BE MORE
21	IMMEDIATE LEGISLATIVE PRIORITIES.
22	SO THE FUNDAMENTAL ITEM DRIVING THE AGENDA
23	FOR TODAY WAS THE REQUEST FROM THE LITTLE HOOVER
24	COMMISSION TO CONSIDER ADDITIONAL OPTIONS RELATED TO
25	BOARD GOVERNANCE, AND THERE WAS A NUMBER OF ITEMS
	22

1	THAT THE LITTLE HOOVER ASKED ABOUT. I THINK IT'S IN
2	THE MATERIALS FOR AGENDA ITEM 3 THAT YOU'VE
3	PREVIOUSLY SEEN. THERE WAS FIVE SPECIFIC ITEMS THAT
4	WERE INITIALLY INCLUDED IN EFFECTIVELY A DERIVATIVE
5	FROM THE LITTLE HOOVER COMMISSION LETTER.
6	SO BREAKING THOSE DOWN INTO THE
7	INCREMENTAL ITEMS THAT WERE RAISED WITH THE LITTLE
8	HOOVER COMMISSION, THEY'RE ASKING IF THEY ASKED
9	ME SPECIFICALLY IF I WROTE THIS BILL TODAY, IS THERE
10	ANY PRACTICE THAT YOU WOULD DO DIFFERENTLY. THE
11	FIRST ITEM WAS IN THEIR QUESTIONS RELATED TO PATIENT
12	ADVOCATES.
13	JEFF, WOULD YOU LIKE TO ADDRESS THAT TOPIC
14	BECAUSE WE'VE DISCUSSED PREVIOUSLY THE ISSUE? WE'VE
15	PREVIOUSLY DISCUSSED THE ISSUE OF PATIENT ADVOCATES.
16	THIS COMES AS A QUESTION DIRECTLY OUT OF THE LITTLE
17	HOOVER COMMISSION MEETING.
18	MR. SHEEHY: WHAT WAS THAT AGAIN, BOB?
19	CHAIRMAN KLEIN: IN THE LITTLE HOOVER
20	COMMISSION MEETING, ONE OF THE THINGS THAT THEY
21	ASKED ME WAS IF I WROTE THIS AGAIN, WOULD I, IN
22	FACT, CHANGE ANY OF THE PROVISIONS RELATED TO
23	PATIENT ADVOCATES. I MEAN ONE OF THE THINGS WE'VE
24	TALKED ABOUT IS ALTERNATES FOR PATIENT ADVOCATES.
25	RI GHT?
	23

DR. POMEROY: I HAVE A QUESTION. ARE YOU
REFERRING TO THE NOVEMBER 26TH LETTER THAT WE
RECEI VED?
CHAIRMAN KLEIN: WELL, THE NOVEMBER 26TH
LETTER WAS AN OUTCOME FROM THE LITTLE HOOVER
COMMISSION HEARING. AND IN THE AREA OF THE BOARD
GOVERNANCE, ONE OF THE THINGS THEY ASKED ABOUT WAS
THE QUESTION OF PATIENT ADVOCATES BECAUSE THERE WAS
QUITE A BIT OF CRITICISM IN THE PUBLIC TESTIMONY
ABOUT PUBLIC PATIENT ADVOCATES NOT BEING ABLE TO
MAKE ALL THE MEETINGS.
NOW, OBVIOUSLY, WITH THE NEW GOVERNANCE
POLICY THAT ALLOWS TELECONFERENCING, WE HAVE TAKEN
AN ACTION TO ADDRESS THAT BECAUSE WE RECOGNIZE THAT
PATIENT ADVOCATES PER SE HAVE MORE CHRONIC DISEASE
IN THEIR FAMILY OR ARE THEMSELVES THE VICTIM OF
CHRONIC DISEASE OR INJURY AND, THEREFORE, NEEDED THE
ACCOMMODATION OF TELECONFERENCING TO FULLY HAVE
ACCESS TO OUR MEETINGS AS A BOARD MEMBER.
DR. POMEROY: THAT DOES NOT APPEAR IN
THE NOVEMBER 26TH LETTER I HAVE, THAT WASN'T ONE OF
THE THINGS THAT THEY QUESTIONED.
CHAIRMAN KLEIN: THERE WAS A COMPLETE
HEARING, CLAIRE, THAT WE ATTENDED AND GAVE
TESTIMONY. DR. SUSAN BRYANT GAVE TESTIMONY.
24

1	DR. POMEROY: RIGHT. RIGHT. SO ARE WE
2	TALKING ABOUT THIS LETTER, OR ARE YOU TALKING ABOUT
3	SOMETHING THAT'S NOT IN THE LETTER?
4	CHAIRMAN KLEIN: I'M TALKING I'M GIVING
5	YOU SOME CONTEXT FOR THE LETTER AND WHAT WAS
6	DISCUSSED IN THE LETTER.
7	MR. SHEEHY: HOW COME A PATIENT ADVOCATE
8	WASN'T INVITED TO TESTIFY BEFORE THE HOOVER
9	COMMISSION? THAT'S MY FIRST. AND, YOU KNOW, I HAVE
10	TO SAY, AND, YOU KNOW, I KNOW YOU'RE STRUGGLING WITH
11	THIS, BOB, BUT THIS WHOLE PROCESS OF LIKE WHICH
12	PIECE OF PROP 71 DO WE WANT TO CHANGE IN WHAT WAY,
13	AND ACTUALLY I DON'T THINK THE ATTENDANCE OF THE
14	PATIENT ADVOCATES IS WORSE THAN FOR SOME OF THE
15	ACADEMIC APPOINTMENTS AND SOME OF THE OTHER FOLKS
16	WHO CAN ACTUALLY TINA NOVA, WHO IS AN INDUSTRY
17	PERSON, HAS SOME OF THE WORST ATTENDANCE OF ANYONE,
18	AND THE SALK REPRESENTATIVE HARDLY EVER SHOWS UP.
19	SO I THINK PATIENT ADVOCATES AS A GROUP
20	PROBABLY SHOW UP MORE THAN OTHER FOLKS. THAT SEEMS
21	LIKE A TOTAL MISREPRESENTATION OF REALITY.
22	CHAIRMAN KLEIN: JEFF, I DID TAKE EXACT
23	I TOOK THE POSITION FIRST OF ALL, TO ANSWER YOUR
24	QUESTION, WE HAD ZERO CONTROL OVER WHO WAS INVITED
25	TO THE LITTLE HOOVER COMMISSION HEARING. THEY
	25
	20

1	SPECIFIED WHO WOULD TALK AND WHAT ORDER THEY WOULD
2	TALK AND HOW LONG THEY COULD TALK.
3	JOHN SIMPSON SPOKE. OBVIOUSLY WE HAVE
4	HEARD HIS POSITIONS BEFORE ON THIS TOPIC. JESSE
5	REYNOLDS SPOKE. TAYMOR SPOKE AND A PROFESSOR FROM
6	STANFORD SPOKE ALL BEFORE DR. BRYANT SPOKE, AND THEN
7	A REPRESENTATIVE OF THE BUCK INSTITUTE WAS INVITED
8	AND WHO SPOKE FOLLOWED BY DR. TROUNSON AND FOLLOWED
9	BY ME.
10	MR. SHEEHY: WAS TAYMOR IDENTIFIED AS A
11	LOBBYIST FOR THE CSU SYSTEM WHEN HE SPOKE?
12	CHAIRMAN KLEIN: NO.
13	MR. SHEEHY: HE PERFORMED THAT, WHICH I
14	ALSO THINK IS A LITTLE SUSPECT ABOUT THAT PROCESS
15	WHEN YOU KNOW, GIVEN SOME OF THE BACK AND FORTH
16	WE HAVE HAD WITH CSU, THAT THEIR PAID LOBBYIST, YOU
17	KNOW, IS MAKING NEGATIVE REPRESENTATIONS ABOUT THE
18	BOARD. I'M VERY UNCOMFORTABLE WITH SOME OF THESE
19	PROCESSES.
20	CHAIRMAN KLEIN: SO, JEFF, BASICALLY I
21	WENT THROUGH AND EXPLAINED THAT THE ISSUES RELATED
22	TO PATIENT ADVOCACY AND HOW IMPORTANT IT IS. I LED
23	OFF A WRITTEN RESPONSE TO THE BOARD WITH A WHOLE
24	DESCRIPTION ABOUT THE PATIENT ADVOCATES AND HOW WE
25	ARE ALL, AS PATIENT ADVOCATES, SEEKING A
	26

1	BREAKTHROUGH IN STEM CELL RESEARCH BECAUSE A
2	BREAKTHROUGH IN ANY AREA HELPS ALL OF THE DISEASE
3	RESEARCH AS IT INFORMS US ON THE PATH TO POTENTIAL
4	THERAPI ES.
5	SO PLEASE BELIEVE THAT THE POSITION THAT
6	PATIENT ADVOCATES ARE HIGHLY STRESSED, ARE ON THE
7	BOARD AND A NUMBER OF ON ALL THE WORKING GROUPS
8	WAS WELL REPRESENTED. I SPECIFICALLY TOOK THE
9	POSITION THE PATIENT ADVOCATES HAVE THE LARGEST
10	I NDI VI DUAL BURDEN.
11	BUT IN TERMS OF DEALING WITH THIS ISSUE,
12	WHAT I WANTED TO DO IS RAISE THIS ISSUE SO THAT WE
13	COULD ADDRESS IT SPECIFICALLY IN THE RESPONSE TO THE
14	BOARD. AND RATHER THAN LOOKING AT THE OBSTACLES TO
15	OTHER PARTS OF THE BOARD BEING ABLE TO ATTEND ALL
16	THE MEETINGS, WHICH HOPEFULLY WILL ALSO BE MITIGATED
17	BY THE TELECONFERENCING CAPACITY, I WAS TRYING TO
18	FOCUS ON WHETHER WE WANTED TO RESPOND TO THEM ABOUT
19	PATIENT ADVOCATES AND THE ISSUE OF ALTERNATES.
20	PERHAPS WHAT I SHOULD DO, THOUGH, IS ASK
21	JAMES TO GIVE US THE LEGAL CONTEXT THAT I WAS
22	WRITING THE INITIATIVE AND HAD TO ADDRESS AND WAS
23	LIMITED IN SO YOU UNDERSTAND WHY IN THE INITIAL
24	DRAFT IT DID NOT INCLUDE ALTERNATES FOR PATIENT
25	ADVOCATES.

1	MR. HARRISON: AS WE WERE DRAFTING THE
2	MEASURE, WE WERE OBVIOUSLY AWARE OF THE LIKELIHOOD
3	THAT THE MEASURE, IF IT WERE ENACTED, WOULD BE
4	CHALLENGED ON CONSTITUTIONAL GROUNDS. AND WHILE WE
5	UNDERSTOOD THE DESIRE FOR ALTERNATES AND MADE AN
6	EFFORT TO ACCOMMODATE THEM IN CONNECTION WITH THE
7	MEMBERS WHO ARE APPOINTED FROM INSTITUTIONS, WE WERE
8	CONCERNED ABOUT THE POSSIBILITY OF A LEGAL CHALLENGE
9	IF WE AFFORDED THE PATIENT ADVOCATES THE SAME
10	OPPORTUNITY FOR THE FOLLOWING REASON.
11	FOR THE MEMBERS WHO ARE APPOINTED FROM
12	INSTITUTIONS, THE CRITERIA THAT ARE SET FORTH FOR
13	APPOINTMENT IN A SENSE RELATE TO THE INSTITUTIONS
14	THEMSELVES. THAT IS, THE OFFICIAL HAS TO BE AN
15	EXECUTIVE OFFICER OF AN INSTITUTION THAT HAS A
16	CERTAIN CAPACITY IN TERMS OF MEDICAL RESEARCH
17	FUNDING AS A PROXY FOR THE EXPERIENCE THAT THE
18	INDIVIDUAL WOULD HAVE.
19	WITH RESPECT TO THE PATIENT ADVOCATES, THE
20	CRITERIA AREN'T SPECIFIC TO AN INSTITUTION, THAT
21	THERE ARE CRITERIA THAT RELATE TO THE INDIVIDUAL IN
22	TERMS OF MEMBERSHIP IN A STATE, LOCAL, OR REGIONAL
23	PATIENT ADVOCACY GROUP IN ONE OF TEN DIFFERENT
24	DI SEASE CATEGORI ES.
25	SO WE WERE CONCERNED WHEN WE WERE DRAFTING
	28

THE MEASURE ABOUT INCLUDING ALTERNATES FOR PATIENT
ADVOCATES FOR THAT REASON. HOWEVER, SINCE THEN, OF
COURSE, THE COURT OF APPEAL HAS UPHELD PROP 71 AND
SPECIFICALLY UPHELD THE LAW AGAINST A CHALLENGE
RELATED TO THE ABILITY OF MEMBERS WHO ARE APPOINTED
FROM INSTITUTIONS TO APPOINT ALTERNATES. SO WE'VE
PASSED THAT LEGAL CHALLENGE AT THIS POINT IN TIME.
MR. SHEEHY: I GUESS I JUST FEEL REALLY
UNCOMFORTABLE ABOUT THIS PROCESS. WE'RE DISCUSSING
PATIENT ADVOCATES WHEN MOST OF THE PATIENT ADVOCATES
AREN'T ON THIS CALL AND THEY'RE NOT AWARE THAT THIS
SUBJECT IS UNDER CONSIDERATION. YOU KNOW, I THINK
IF WE'RE GOING TO TALK ABOUT PROPOSING CHANGES TO
PROP 71 ON BEHALF OF THE ADVOCATES, SINCE THE
ADVOCATES ARE A SUBJECT OF THE DISCUSSION, WHICH I
WAS NOT AWARE OF UNTIL THIS MOMENT WE WERE A
PARTICULAR FOCUS AT THE LITTLE HOOVER COMMISSION.
YOU KNOW, I'M VERY UNCOMFORTABLE WITH THIS
PROCESS.
CHAIRMAN KLEIN: JEFF, THE PROCESS IS TO
IDENTIFY AREAS OF INTEREST HERE AND THEN BRING IT TO
THE BOARD WHERE EVERYONE IS PRESENT. SO WE'RE NOT
GOING TO MAKE ANY DEFINITIVE RESPONSES. THIS IS
JUST PART OF A PROCESS TO TRY AND IDENTIFY AREAS.
THE REASON THAT I SPECIFICALLY ASKED YOU
20

1	IS THAT YOU'VE PREVIOUSLY RAISED THE ISSUE OF
2	ALTERNATES.
3	MR. SHEEHY: I HAVE NOT ACTUALLY.
4	DR. PRIETO: JEFF, COULD I SPEAK FOR A
5	MINUTE BECAUSE I THINK I'M THE ONE WHO'S RAISED THE
6	ISSUE. AND, CLAIRE, IF I'M NOT MISTAKEN, WAS YOUR
7	QUESTION JUST WHETHER THIS WAS PROPERLY AGENDIZED?
8	DR. POMEROY: WELL, I'M JUST TRYING TO
9	CLARIFY WHAT WE'RE RESPONDING TO, YES.
10	DR. PRIETO: JUST TO GIVE MY OPINION, ONE,
11	I THINK IT WAS PROPERLY AGENDIZED. IF YOU READ THE
12	LETTER, IT JUST ASKS THE FIRST POINT ON THE
13	NOVEMBER 26TH LETTER IS PRETTY OPEN-ENDED SAYING
14	WOULD YOU WRITE ANYTHING DIFFERENTLY IN THE
15	INITIATIVE, AND THEN GOING INTO A FEW GENERAL AREAS,
16	BUT NOT SO MUCH SPECIFICS.
17	SO I THINK WE'RE CERTAINLY WITHIN OUR
18	RIGHTS DISCUSSING THIS. AS YOU KNOW, I'VE DISCUSSED
19	THIS WITH SOME OF THE OTHER ADVOCATES AND HAVE
20	BROUGHT IT UP IN MEETINGS. I UNDERSTAND JAMES
21	JAMES HAS EXPLAINED TO ME BEFORE THE LEGAL REASONING
22	THAT HE JUST LAID OUT. AND I GUESS I SORT OF
23	ACCEPTED IT GRUDGINGLY, BUT I DON'T PARTICULARLY
24	LIKE IT.
25	I THINK THAT I HAD HEARD THAT THERE WAS
	30
	JU

1	SOME CRITICISM OF ADVOCATES FOR NOT HAVING GOOD
2	ATTENDANCE. WHEN I'VE HEARD THAT, MY RESPONSE HAS
3	BEEN I THINK THE PEOPLE WHO HAVE HAD ATTENDANCE
4	PROBLEMS ARE ADVOCATES WHO HAVE PARTICULAR
5	CHALLENGES THAT MAKE IT VERY EITHER PERSONAL OR
6	FAMILY WITH REGARDS TO THE CHRONIC DISEASE THEY'VE
7	ADVOCATED FOR THAT MAKE IT VERY UNDERSTANDABLE THAT
8	THEY CAN'T MAKE ALL THE MEETINGS.
9	AND I WOULD THINK, AND THIS WOULD BE UP TO
10	JAMES OR SOME OF OUR COUNSEL, THAT THERE WOULD BE
11	LANGUAGE THAT COULD BE WRITTEN THAT WOULD
12	ACCOMMODATE AN ALTERNATE BEING APPOINTED FOR AN
13	ADVOCATE WHO FELT THEY MIGHT NEED ONE WHO WOULD COME
14	FROM THE ADVOCACY COMMUNITY AROUND THE SAME DISEASE
15	OBVIOUSLY. IT WOULD NOT NECESSARILY BE SOMEBODY
16	FROM THE SAME ORGANIZATION. IN SOME CASES THERE MAY
17	NOT EVEN BE AN ORGANIZATION, BUT SOMEBODY WHO HAS A
18	RECORD OF ADVOCACY AROUND THE ISSUE.
19	CHAIRMAN KLEIN: FRANCISCO, IF IT WERE
20	HANDLED IN THE SAME MANNER WITH THE OTHER
21	APPOINTMENTS TO THE BOARD, THE ADVOCATES THEMSELVES
22	COULD APPOINT THEIR OWN ALTERNATE.
23	DR. PRIETO: WELL, IF THAT WOULD PASS
24	LEGAL MUSTER, SURE, I'M ALL FOR THAT. I MEAN
25	OBVIOUSLY I KNOW THE SOURCES IN MY ASSOCIATION AND

IN DIABETES ADVOCACY IN GENERAL WHO I WOULD GO BACK
TO TO SOLICIT NAMES AND RECOMMENDATIONS. BUT, YOU
KNOW, WHATEVER PROCESS. THE PROCESS WOULD HAVE TO
BE, YOU KNOW, WHATEVER COUNSEL TOLD US WOULD BE
APPROPRIATE. AND THEN I THINK IT WOULD BE A BENEFIT
FOR US.
CHAIRMAN KLEIN: AND JUST FOR
CLARIFICATION, THE OUTCOME OF THE DISCUSSION WE'RE
IN IS THEORETICALLY TO BRING IDEAS BACK TO THE BOARD
FOR DISCUSSION AT THE FULL BOARD. THERE'S NOT AN
IDEA THAT WE'RE GOING TO WRITE LANGUAGE HERE TODAY.
THERE'S NOT AN IDEA THAT WE'RE GOING TO PASS SOME
VERY SPECIFIC RECOMMENDATION. THIS IS A IF YOU
LOOK AT THIS LETTER FROM NOVEMBER 26TH AND YOU LOOK
AT THE HOURS OF TESTIMONY IN THE HEARING, THIS IS A
PRETTY COMPLICATED QUESTION THEY'RE ASKING.
SO ANOTHER
DR. PRIETO: QUITE OPEN-ENDED.
CHAIRMAN KLEIN: TO PUT ANOTHER ISSUE ON
THE TABLE HERE, ONE OF THE OTHER ANOTHER ISSUE ON
GOVERNANCE THEY ASKED IS WHAT ABOUT STAGGERED TERMS.
NOW, WE DO HAVE STAGGERED TERMS OF SIX- AND
EIGHT-YEAR APPOINTMENTS. HOWEVER, THE POINT, I
THINK, THAT THEY HAD IMPLICIT IN THAT, IF I
UNDERSTAND PROPERLY, IS THAT WHILE I WROTE IT TO GET
3.7

1	SOME INITIAL STABILITY FOR A LONG PERIOD IN THE
2	BEGINNING OF THIS INSTITUTION, WHAT WILL HAPPEN IS
3	AT SIX YEARS, THERE WILL BE A SUBSTANTIAL PORTION OF
4	THE BOARD, NOT HALF BECAUSE THE FIVE DEANS SIT
5	PERMANENTLY, AND AT EIGHT YEARS YOU HAVE A VERY
6	SUBSTANTIAL TURNOVER IN THE BOARD. SHOULD THERE BE
7	MORE STAGGERING TO THE BOARD TERMS ON TURNOVER SO
8	THAT SOME OF THOSE POSITIONS BECOME FOUR-YEAR
9	APPOINTMENTS, SOME ARE FOUR, SOME ARE SIX, SO YOU
10	GET BETTER CONTINUITY? IT'S ANOTHER QUESTION THAT
11	THEY PUT ON THE TABLE.
12	IS THERE ANY DISCUSSION ON THAT POINT?
13	MR. SHEEHY: HOW ARE WE DECIDING WHICH
14	QUESTIONS THAT CAN BE ON THE TABLE? I MEAN IT JUST
15	SEEMS SOMEWHAT RANDOM AND SCATTER SHOT.
16	CHAIRMAN KLEIN: WHAT I'M TRYING TO DO IS
17	GO THROUGH FOR YOU AND HIGHLIGHT POINTS THAT THEY
18	RAISED AT MULTIPLE HOUR DISCUSSIONS. THEY DID NOT
19	PRIORITIZE THESE POINTS, JEFF. WHAT I'M TRYING TO
20	DO IS IDENTIFY POINTS FOR DISCUSSION AT THIS POINT.
21	DR. POMEROY: BOB, THIS IS CLAIRE. SO MY
22	QUESTION IS THIS. THIS LETTER WAS WRITTEN TO YOU,
23	AND IT ASKS YOUR OPINION ON THINGS. IS YOUR
24	INTENTION TO WRITE A LETTER IN RESPONSE THAT
25	EXPRESSES YOUR OPINION, OR IS IT YOUR INTENTION TO

OR IS IT YOUR BCOMMITTEE TO LOOK EHALF OF THE WHAT THE GOAL IS  OF THIS IS TO MADE IT VERY FOR IS WHAT WOULD TIVE CHANGES. SO Y' RE SUGGESTING ILL BE SOME
EHALF OF THE WHAT THE GOAL IS  OF THIS IS TO MADE IT VERY FOR IS WHAT WOULD TIVE CHANGES. SO Y' RE SUGGESTING ILL BE SOME
NHAT THE GOAL IS  OF THIS IS TO  MADE IT VERY  FOR IS WHAT WOULD  TIVE CHANGES. SO  Y' RE SUGGESTING  ILL BE SOME
L OF THIS IS TO  MADE IT VERY  FOR IS WHAT WOULD  TIVE CHANGES. SO  Y' RE SUGGESTING  ILL BE SOME
MADE IT VERY FOR IS WHAT WOULD TIVE CHANGES. SO Y'RE SUGGESTING ILL BE SOME
MADE IT VERY FOR IS WHAT WOULD TIVE CHANGES. SO Y'RE SUGGESTING ILL BE SOME
FOR IS WHAT WOULD TIVE CHANGES. SO Y'RE SUGGESTING ILL BE SOME
TIVE CHANGES. SO Y'RE SUGGESTING ILL BE SOME
Y'RE SUGGESTING
ILL BE SOME
TO ME CDECLELCALLY
ED ME SPECIFICALLY
ON.
YOU. SO ARE YOU
NOT. I'M NOT. I
WOULD BE
TO RESPOND
E IT THROUGH THE
OARD AND GET
ATE A SUBCOMMITTEE
Y WANT TO KNOW ON
GES IN THE
GES IN THE
WOULD BE TO RESPOND E IT THROUGH THE DARD AND GET ATE A SUBCOMMITTEE

1	I WAS UNWILLING TO TAKE A POSITION BECAUSE
2	I FELT THAT IT SHOULD GO THROUGH A PROCESS WITHIN
3	OUR OWN BOARD. AND WHAT WE'RE DOING TODAY IS
4	INITIATING DISCUSSION ON WHAT ITEMS WE WILL HAVE IN
5	A LATER DISCUSSION WITH THE BOARD.
6	MR. SHEEHY: YOU'RE IDENTIFYING THE ITEMS,
7	BOB. SO I WOULD RATHER YOU JUST WROTE THE LETTER
8	BASED ON THE ITEMS THAT YOU THINK ARE IMPORTANT
9	RATHER THAN GET YOU KNOW, YOU'RE NOT IDENTIFYING
10	ANY OF THE ITEMS THAT I, BASED ON MY EXPERIENCE IN
11	THE WORKING GROUPS AND THE MEETINGS OF THE BOARD
12	THAT I'VE ATTENDED, THAT I MIGHT THINK ARE IMPORTANT
13	CHANGES THAT NEED TO BE MADE TO MAKE THE BOARD RUN
14	BETTER OR MAKE THE STRUCTURE BETTER. I WOULD RATHER
15	LEAVE IT ALONE.
16	YOU KNOW, OTHER MEMBERS, WE PRESUMABLY
17	HAVE 29 SEPARATE OPINIONS ON WHAT CHANGES MIGHT WORK
18	FOR MAKING THE ICOC STRUCTURE BETTER. I JUST FEEL
19	REALLY UNCOMFORTABLE. I MEAN I FEEL LIKE I'M KIND
20	OF YOU'RE ASKING ME TO AGREE WITH THE CHANGES
21	THAT YOU'VE IDENTIFIED IN THE DISCUSSIONS YOU HAD
22	WITH THE HOOVER COMMISSION THAT I WASN'T AT. WILL I
23	GO ALONG WITH THOSE WHEN I MAY HAVE OTHER ISSUES
24	THAT ARE MUCH MORE IMPORTANT TO ME THAT I WOULD LIKE
25	TO SEE CHANGED?

IF WE'RE GOING TO HAVE A PROCESS TO CHANGE
THIS, I THINK WE SHOULD FIRST OF ALL, I THINK IT
SHOULD START IN GOVERNANCE BECAUSE THAT'S WHERE THE
GOVERNANCE OF THE BOARD HAS BEEN ENTRUSTED AND, YOU
KNOW, WHERE ISSUES WHERE THE BOARD MAY NOT BE
FUNCTIONING WELL HAVE BEEN IDENTIFIED.
BUT, AGAIN, I DON'T SEE I GOT TO TELL
YOU FRANKLY I DON'T SEE A BIG, LONG PROCESS ABOUT A
WISH LIST FOR WHAT WOULD MAKE PROP 71 BETTER BEING A
GOOD USE OF THIS BOARD'S TIME AT THIS JUNCTURE. WE
HAVE A LOT MORE SIGNIFICANT CHALLENGES IN FRONT OF
US, AND WHAT I WOULD PREFER IS THEY'RE NOT IF
THEY REALLY WANT TO ENGAGE US ON A PROCESS, A
COOPERATIVE PROCESS OF CHANGING PROP 71, THEN THEY
SHOULD APPOINT SOME MEMBERS OF THEIR BOARD WITH SOME
MEMBERS OF OUR BOARD AND START A REAL PROCESS. BUT
IF IT'S JUST ASKING US FOR SOME COMMENTS, I THINK
IT'S NOT A GOOD, FAIR PROCESS. AND I'D RATHER SAY
THAT WHAT WE HAVE NOW IS WORKING, WHICH IT IS, AND
PLEASE LET US DO OUR WORK THAN GET THIS TRIM AROUND
THE EDGES, THIS ONE, THAT ONE.
IF IT'S NOT GOING TO BE AN EXHAUSTIVE
DETAILED LOOK AT THE SHORTCOMINGS AND THE STRONG
POINTS OF PROP 71 WITH A COMPLETE PROCESS WITH SOME
BUY-IN TO MAKE CHANGES, THEN I THINK THIS IS AN

1	INCREDIBLE WASTE OF OUR TIME WHEN, AS YOU TALK AS
2	WE'VE ALREADY NOTED, THERE ARE THINGS THAT NEED TO
3	BE DONE AT THE FEDERAL LEVEL. YOU KNOW, WE'RE STILL
4	WORKING WE'RE STILL WORKING ON TRYING TO GET A
5	STRATEGIC PLAN FOR THIS INSTITUTE. YOU KNOW, I MEAN
6	I CAN GO DOWN THE LIST. WE'RE STILL TRYING TO GET
7	GRANTS OUT. WE'RE STILL TRYING TO FIGURE OUT A
8	PRESCREENI NG PROCESS.
9	SO THERE'S A LOT OF THE NITTY-GRITTY STUFF
10	ABOUT OUR WORK WE NEED TO DO. AND I GIVEN THAT I
11	DON'T THINK ANYTHING WILL PASS THE LEGISLATURE, I
12	WOULD RATHER TAKE THE OPINION, THANKS, BUT NO THANKS
13	RI GHT NOW.
14	CHAIRMAN KLEIN: OKAY. HOW DO OTHER
15	MEMBERS FEEL?
16	DR. PRIETO: WELL, I HAVE, YOU KNOW, MY
17	PARTICULAR ISSUE THAT I BROUGHT UP. AND I, YOU
18	KNOW, WOULD LIKE TO SEE THAT ADDRESSED IN SOME WAY.
19	I'M NOT GOING TO SAY THAT IT IS THE HIGHEST PRIORITY
20	OF THE BOARD. I'D CERTAINLY BE WILLING TO TALK WITH
21	YOU, JEFF, OR ANYONE ELSE ABOUT WHAT'S THE MOST
22	APPROPRIATE PROCESS FOR PROPOSING CHANGES LIKE THAT.
23	THIS LITTLE HOOVER COMMISSION QUESTION, I THINK,
24	JUST SORT OF OPENED THE DOOR FOR US TO RESPOND.
25	MR. SHEEHY: I CAN THINK OF FIVE OR SIX

1	THINGS. I MEAN I WOULD LIKE TO DO AWAY WITH THE
2	PROHIBITION ON COMPENSATION FOR RESEARCH DONATIONS.
3	IS THAT APPROPRIATE, YOU KNOW? AND HOW WILL PEOPLE
4	REACT IF THAT'S PART OF THIS? YET WE'RE SEEING IN
5	THE STANDARDS WORKING GROUP THAT THAT ACTUALLY MAY
6	HAVE A NEGATIVE IMPACT ON SOMATIC CELL DONATIONS FOR
7	I PS EXPERIMENTS.
8	DR. PRIETO: WHAT WOULD BE A PROCESS WHERE
9	WE COULD, YOU KNOW, LOOK AT THESE MORE
10	SYSTEMATICALLY AND PROPOSE SOME CHANGES?
11	CHAIRMAN KLEIN: SO, JEFF, YOU KNOW, HOW
12	WOULD YOU FEEL IF WE WERE TO COLLECT LEGISLATIVE
13	CHANGES THAT YOU WOULD SUGGEST? YOU KNOW, THERE ARE
14	POTENTIAL CHANGES BECAUSE OF THE FACT THAT THEY JUST
15	FROZE THE PMI PROGRAM. WE DON'T HAVE FUNDS AT THE
16	MOMENT TIED UP IN THE PMI PROGRAM, BUT THERE ARE
17	POTENTIAL CHANGES THAT WE COULD MAKE THAT MIGHT BE
18	HELPFUL IN THE FINANCE AREA. YOU JUST TALKED ABOUT
19	THE DONATION, FINANCIAL DONATION AREA. FRANCISCO
20	HAS TALKED ABOUT PREVIOUSLY IN BOARD MEETINGS
21	ALTERNATES.
22	PERHAPS WHAT WE SHOULD DO IS TWO THINGS.
23	ONE, GET EVERYONE A COPY OF THE TRANSCRIPT OF THAT
24	MEETING SO YOU CAN SEE IN GREAT DEAL WHAT THE
25	CRITICISMS WERE AND WHAT THE RESPONSES WERE AND GET

1	THE INDIVIDUAL MEMBERS TO, AS A FIRST STEP, GIVE US
2	A BULLET POINT LETTER JUST CAPTURING IDEAS ON THINGS
3	THAT THEY THINK WOULD ENHANCE OUR OVERALL FUNCTION.
4	LEGISLATION IS THE SUBJECT OF THIS
5	PARTICULAR REQUEST THEY'RE MAKING THAT I'M INVOLVED
6	I N.
7	MR. SHEEHY: THEY DIRECTED THIS TO YOU,
8	BOB, AND THEY HAVEN'T REALLY ENGAGED US AS A BOARD.
9	AND I'M UNCOMFORTABLE GIVEN THAT THEY HAVEN'T ASKED
10	US AS A BOARD TO RESPOND. I MEAN YOU CAN RESPOND AS
11	YOU WOULD LIKE, BUT I REALLY DON'T THINK THIS IS A
12	BOARD MATTER AT THIS TIME. SO ULTIMATELY BECAUSE
13	THE REQUEST IS TO YOU, I MEAN, IN ALL FAIRNESS, WE
14	CAN'T DIRECT YOU AS A BOARD ON HOW TO RESPOND TO
15	THIS. YOU'RE THE PERSON WHO WROTE THE PROPOSITION.
16	SO I THINK THIS IS AGAIN, I COME TO USE
17	OF TIME, I MEAN, AND FAIRNESS AND ALL OF THESE
18	THINGS. YOU KNOW, I JUST DON'T THINK THAT WE REALLY
19	ARE INITIATING A GOOD FAITH ENDEAVOR TO TRY TO OFFER
20	UP COOPERATIVELY AMENDMENTS TO PROP 71 THAT MIGHT
21	ENHANCE ITS FUNCTION. IT SEEMS MORE LIKE IT
22	DOESN'T HAVE THAT FEEL. THERE HASN'T BEEN ENOUGH
23	DIALOGUE WITH THE BOARD AS A WHOLE WITH THE LITTLE
24	HOOVER COMMISSION TO SUGGEST THAT WE'RE STARTING ON
25	THAT PROCESS.
	39

1	CHAIRMAN KLEIN: WELL, JEFF, WE'VE GOT TO
2	ALWAYS START A PROCESS SOMEWHERE. RATHER THAN GOING
3	TO THE BOARD WITHOUT ANY BACKGROUND DISCUSSION, THE
4	DESIRE WAS TO FIRST GO TO THE LEGISLATIVE COMMITTEE
5	BECAUSE THEY'RE LOOKING AT LEGISLATION THAT HAS A
6	BROAD SCOPE TO IT BETWEEN FINANCE ISSUES,
7	APPOINTMENT PROCESS, TERMS OF APPOINTEES, ISSUES
8	THAT YOU JUST RAISED.
9	SO HERE'S WHAT I'D LIKE TO DO IS, FIRST OF
10	ALL, WE'VE HEARD FROM TWO OF THE MEMBERS ON THIS
11	CALL. I'D LIKE TO SEE IF ANY OF THE OTHER MEMBERS
12	WOULD LIKE TO SPEAK TO IT, BUT WHAT I'D LIKE TO DO
13	IS GET EVERYONE A FULL TRANSCRIPT.
14	DR. POMEROY: BOB, WHY DON'T WE SPEAK TO
15	IT FIRST BEFORE YOU PUT YOUR PROPOSAL OUT. I'D LIKE
16	TO SPEAK TO IT. SO, YOU KNOW, THIS IS MY CONFUSION
17	IS THAT TO ME IT APPEARS THAT THIS LETTER IS WRITTEN
18	TO YOU ABOUT YOUR TESTIMONY. AND IT'S ASKING YOUR
19	OPINION ABOUT WRITING THE INITIATIVE, WHICH WAS THE
20	PROCESS THAT HAPPENED BEFORE THE BOARD EVEN EXISTED.
21	SO IT SEEMS TO ME THAT IT IS APPROPRIATE FOR YOU TO
22	CLARIFY YOUR PERSONAL TESTIMONY IN RESPONSE TO THIS
23	LETTER.
24	I'M SURE, SINCE THERE ARE LITTLE HOOVER
25	COMMISSION MEMBERS HERE, THAT IF THEY WISH TO HEAR
	40

1	FROM THE ENTIRE MEMBERSHIP OF THE BOARD, THEY CAN
2	WRITE LETTERS TO THE ENTIRE BOARD. BUT I INTERPRET
3	THIS LETTER AS A LETTER TO YOU ABOUT YOUR PERSONAL
4	TESTI MONY.
5	CHAIRMAN KLEIN: OKAY. WELL, DR. POMEROY,
6	IN RESPONSE TO THE QUESTIONS THAT IS AT THE HEART OF
7	THIS LETTER TO ME, I TOOK THE POSITION IN MY
8	TESTIMONY THAT PRIOR TO MAKING ANY RECOMMENDATIONS
9	ON LEGISLATIVE CHANGES, THAT I FELT IT WAS IMPORTANT
10	FOR ME TO CONFER WITH THE LEGISLATIVE COMMITTEE AND
11	THE BOARD TO TRY AND GET A SENSE OF THE BOARD
12	BECAUSE I FELT IT WAS APPROPRIATE TO UNDERSTAND FROM
13	EVERYONE'S EXPERTISE AND LEARNING EXPERIENCE IN
14	DEALING WITH THIS INSTITUTION, LIKE FRANCISCO'S VERY
15	IMPORTANT POSITION THAT THE ALTERNATES TO THE BOARD
16	ARE AT THE HIGHEST STRESS LEVEL OF ANY PART OF THE
17	MEMBERSHIP BECAUSE THEY PARTICIPATE IN ALL THE
18	WORKING GROUPS PLUS PATIENT ADVOCATES ARE AT THE
19	HIGHEST STRESS LEVEL BECAUSE THEY PARTICIPATE IN ALL
20	THE WORKING GROUPS, PLUS THE SUBCOMMITTEES, PLUS THE
21	BOARD.
22	SO MY POSITION TO THE LITTLE HOOVER
23	COMMISSION WAS THAT I DIDN'T WANT TO RESPOND
24	INDIVIDUALLY. I WANTED TO RESPOND FROM
25	UNDERSTANDING AT THE BOARD LEVEL WHAT THE CONSENSUS

1	WAS. I'M JUST TRYING TO START THAT DISCUSSION AT
2	THIS POINT. THAT'S WHY I SUGGEST THAT IF EVERYONE
3	HAS A COPY OF THE TESTIMONY THAT OCCURRED AT THE
4	LITTLE HOOVER COMMISSION, IT MIGHT PROVIDE THEM WITH
5	THE DEPTH OF WHAT THE ISSUES WERE THAT WERE LOOKED
6	AT AND WHAT THE RESPONSES WERE AT THE TIME.
7	MR. SHEEHY: ISN'T THE QUESTION YOU'RE
8	ASKING US IS REALLY IN A WAY THE SAME QUESTION THAT
9	YOU WERE ASKED BY THE LITTLE HOOVER COMMISSION?
10	WHAT WOULD YOU CHANGE? SO WHATEVER TESTIMONY THAT
11	TOOK PLACE AT THE LITTLE HOOVER COMMISSION IS,
12	FRANKLY, IRRELEVANT BASED ON OUR OWN PERSONAL
13	EXPERIENCE OF TRYING TO WORK THROUGH IN THE TIME
14	THAT WE'VE BEEN ON THIS BOARD WHATEVER ISSUES OR
15	CHALLENGES WE'VE BEEN CONFRONTED WITH.
16	DR. PRIETO: NOT TO PUT WORDS IN BOB'S
17	MOUTH, BUT I THINK WHAT HE'S SAYING IS THAT BEFORE
18	HE WOULD ANSWER THAT QUESTION, HE'D WANT TO KNOW
19	WHAT THE BOARD THINKS OR THE MEMBERS OF THE BOARD
20	WHO ARE MORE DIRECTLY AFFECTED BY SOME OF THESE
21	QUESTIONS. YOU KNOW, SINCE I HAVE AN OPINION ON ONE
22	PARTICULAR ISSUE ESPECIALLY, I GUESS I APPRECIATE
23	THAT. I THINK THAT'S A REASONABLE QUESTION TO ASK
24	AND PROCESS TO START, TO ASK US TO SORT OF TOSS THE
25	BALL IN OUR COURT AND SAY, WELL, OKAY. I THINK I'D

1	WANT TO KNOW WHAT THE BOARD THINKS AND WHAT DOES THE
2	BOARD THINK?
3	CHAIRMAN KLEIN: EXACTLY. WE'RE JUST
4	STARTING A PROCESS TO UNDERSTAND WHAT THE BOARD
5	THINKS SO THAT WE CAN GIVE THEM SO THAT THE
6	RESPONSE CAN REALLY BE REPRESENTATIVE OF A SPECTRUM.
7	THE BOARD DOES NOT NECESSARILY NEED TO COME TO A
8	UNIFORM RESPONSE ON EVERYTHING. WE COULD GIVE THEM
9	MAJORITY RESPONSE AND MINORITY RESPONSE. TRYING TO
10	BE I'M TRYING TO BE OPENLY RESPONSIVE TO THE
11	BOARD AND MAKE SURE THAT I GET ALL THE IDEAS. I'M
12	TRYING TO BE OPEN AND RESPONSIVE TO THE LITTLE
13	HOOVER COMMISSION AND TRYING TO GET ALL THE IDEAS OF
14	THE TREMENDOUS EXPERTISE AND EXPERIENCE THAT THIS
15	BOARD HAS ACCUMULATED.
16	SO AT THIS POINT ARE THERE ANY OTHER
17	MEMBERS WHO WOULD LIKE TO COMMENT ON THIS, OR IS
18	THERE ANY AT LEAST WHAT I WOULD LIKE TO DO, AS I
19	SAID, IS SEE WHAT THE RESPONSES OF THE MEMBERS ARE
20	AFTER THEY HAVE THE LITTLE HOOVER COMMISSION
21	TESTIMONY, AND THAT ANY RESPONSES FROM INDIVIDUAL
22	MEMBERS OF THE BOARD THAT ARE HELPFUL IN IDENTIFYING
23	ISSUES, WHETHER THEY WERE RAISED IN THE LITTLE
24	HOOVER COMMISSION OR NOT, WHETHER THEY WERE RAISED
25	BY THE COMMISSION OR NOT, WE NEED TO GET SOME ISSUES
	40

1	ON THE TABLE TO BEGIN TO DISCUSS THEM.
2	I DO AGREE WITH JEFF'S POSITION, THAT WE
3	CLEARLY HAVE A HUGE NUMBER OF PRIORITIES ON US RIGHT
4	NOW. THAT POINT WAS MADE BY DR. TROUNSON TO THE
5	COMMITTEE, AND I THINK THAT THEY UNDERSTAND THAT.
6	I'M JUST TRYING TO BE RESPECTFULLY RESPONSIVE. AND
7	I THINK FRANCISCO DID AN EXCELLENT JOB OF
8	SUMMARIZING IT.
9	SO IS THERE ANY OTHER DISCUSSION FROM THE
10	BOARD? OTHERWISE, WE WILL TABLE THIS UNTIL WE CAN
11	GET AN ADDITIONAL RESPONSE UNTIL PEOPLE HAVE THE
12	ABILITY TO LOOK AT THE LITTLE HOOVER COMMISSION AND
13	REALLY DECIDE IF THEY HAVE A PARTICULAR RESPONSE TO
14	ANY OF THESE ISSUES.
15	DR. POMEROY: WHAT WILL THE PROCESS BE
16	AFTER THAT?
17	CHAIRMAN KLEIN: WELL, IF THERE'S AN
18	IDENTIFICATION OF ISSUES, IT WILL THEN GO TO THE
19	BOARD. AND THE BOARD WILL BE WE'LL MAKE
20	AVAILABLE TO THE WHOLE BOARD ALL OF THE TESTIMONY.
21	AND THEN THE BOARD AS A WHOLE, I THINK, CAN BRING UP
22	ANY QUESTIONS OR POINTS THEY HAVE FROM FINANCE
23	THROUGH APPOINTMENTS. AND THEN WE PROBABLY WOULD
24	HAVE A SUBCOMMITTEE THAT GETS SET UP TO TRY AND DEAL
25	WITH THIS ISSUE TO DEVELOP, PERHAPS IN A PUBLIC

1	HEARING, SOME DISCUSSION. I DON'T WANT TO PREJUDGE
2	THE PROCESS FOR THE BOARD.
3	DR. POMEROY: I GUESS MY QUESTION, BOB, IS
4	HOW TO DO THIS EXPEDITIOUSLY. SO I HEAR WHAT YOU
5	ARE SAYING, WHICH IS THAT YOU WANT TO GET BROADER
6	INPUT INTO YOUR RESPONSE. SO IF YOU DISTRIBUTE THE
7	TESTIMONY WHICH GIVES US SOME BACKGROUND, AND JAMES
8	MAY HAVE TO ANSWER THIS QUESTION, CAN WE ALL E-MAIL
9	YOU WITH OUR TOP FIVE IDEAS AND THEY SOMEHOW GET
10	INCORPORATED FOR A DISCUSSION? IT JUST SEEMS LIKE
11	THERE'S A MORE EFFICIENT WAY TO DO THIS.
12	CHAIRMAN KLEIN: YOU CAN E-MAIL ME YOUR
13	TOP FIVE OR TEN IDEAS. THE ISSUE IS WE CAN'T HAVE
14	CROSS DISCUSSION BETWEEN LARGE NUMBERS OF MEMBERS
15	BECAUSE OF BAGLEY-KEENE. BUT IF THOSE IDEAS ARE
16	SENT TO ME, I WILL AGGREGATE THOSE IDEAS SO THAT WE
17	CAN COME BACK WITH A PUBLIC DISCUSSION OF THEM.
18	DR. POMEROY: ARE YOU PLANNING TO DO THIS
19	JUST TO THE LEGISLATIVE SUBCOMMITTEE MEMBERS OR TO
20	ALL THE BOARD MEMBERS?
21	CHAIRMAN KLEIN: WELL, INITIALLY JUST
22	THROUGH THE LEGISLATIVE SUBCOMMITTEE TO GET SOME
23	STARTING POINTS TO DEVELOP SOME INFORMATION. THEN
24	I'M GOING TO ASK WHEN IT GOES TO THE BOARD, WE'RE
25	GOING TO ASK ALL THE BOARD MEMBERS TO COME UP WITH
	45

1	THEIR IDEAS SO THAT WE CAN GET THE ENTIRE SCOPE.
2	I'D ALSO ASK THE STAFF TO COME UP WITH ANY IDEAS
3	BECAUSE I DON'T THINK THIS SHOULD BE PIECEMEAL. SO
4	THAT IF THERE ARE A LIST OF ITEMS WITH OUR
5	EXPERIENCE WITH OVER FOUR YEARS NOW THAT WOULD BE
6	HELPFUL ACROSS THE SPECTRUM, WHETHER DEALING WITH
7	PEER REVIEW OR FINANCE OR ANY OTHER AREA, THAT WE
8	CAN INTEGRATE THEM.
9	I DO KNOW IN THE FINANCE AREA THERE'S SOME
10	ITEMS NOW THAT WOULD BE VERY HELPFUL.
11	DR. LEVIN: IT SEEMS TO ME THAT IF I
12	AGREE WITH JEFF AND CLAIRE ABOUT THAT THIS WAS A
13	REQUEST TO YOU ABOUT WHAT YOU THINK SHOULD HAVE BEEN
14	CHANGED OR SHOULD MAYBE BE CHANGED MOVING FORWARD TO
15	PROP 71. AND IF YOUR INTENTION IS JUST TO GET
16	EVERYBODY ELSE'S INPUT INTO THAT BEFORE YOU GIVE
17	YOUR RESPONSE, THEN IT SEEMS THE BEST WAY AND
18	EASIEST WAY TO DO THAT IS JUST PUT A BROAD CALL OUT
19	TO ALL ICOC MEMBERS AND ALL STAFF MEMBERS AT CIRM TO
20	PLEASE ANSWER THESE QUESTIONS OR GIVE YOUR TOP FIVE
21	OR TEN SUGGESTIONS OF WHAT COULD BE CHANGED, SEND
22	THEM ALL IN BY E-MAIL. YOU CAN COLLECT THEM AND
23	THEN MAKE THAT AN AGENDA ITEM TO DISCUSS IN JANUARY
24	THE TOP TEN THINGS THAT CAME UP FROM EVERYBODY.
25	CHAIRMAN KLEIN: OKAY. THAT SOUNDS LIKE A

1	GOOD STARTING POINT. THAT GETS US A BROADER SCOPE
2	I MMEDI ATELY.
3	DOES ANYONE HAVE AN OBJECTION TO ASKING
4	EVERYONE AT THIS TIME FOR THEIR RESPONSE TO THAT?
5	MR. SHEEHY: I DON'T. BUT I REALLY,
6	REALLY HAVE TO SAY THAT I THINK THAT THIS IS A VERY,
7	VERY BAD IDEA. THAT THE WHOLE PROCESS I THINK IF
8	WE'RE GOING TO GO THROUGH A PERIOD OF
9	SELF-EXAMINATION, THAT IT SHOULD HAVE A COHERENT
10	STRUCTURE, A COHERENT PLAN. I ACTUALLY THINK THAT
11	WE'RE FUNCTIONING, THAT WE ARE ACHIEVING OUR
12	MISSION, THAT WE HAVE AN ENORMOUS SET OF CHALLENGES
13	IN FRONT OF US IF WE'RE GOING TO FULFILL THE
14	PROMISES THAT WE MADE TO THE VOTERS BOTH IN THE
15	STRATEGIC PLAN AND THAT YOU DID WHEN YOU PASSED PROP
16	71.
17	AND TO ENGAGE IN THIS PROCESS AT THIS TIME
18	WILL BE DESTRUCTIVE, THAT IT WILL NOT BE
19	ESPECIALLY IN THE WAY IT'S BEING CONSTRUCTED, THAT
20	MY PERSONAL PREFERENCE WOULD BE TO SAY, WHICH IS
21	WHAT WE SAID WHEN THE ISSUE OF THE LITTLE HOOVER
22	COMMISSION CAME UP LAST YEAR IN LEGISLATION, IS THAT
23	AT THIS TIME WE WERE NOT PREPARED TO ENGAGE IN
24	EXAMINATION AND REWRITING OF PROP 71. I JUST SIMPLY
25	THINK THE KIND OF EXHAUSTIVE ANALYSIS THAT REALLY
	47

1	SHOULD BE DONE BEFORE WE START TALKING ABOUT
2	CHANGING SOME OF THE THINGS THAT WE'RE DOING ISN'T
3	TAKING PLACE.
4	AND, YOU KNOW, I CAN ANTICIPATE NEGATIVE
5	OUTCOMES TO THIS PROCESS, AND I WOULD RATHER SAY
6	THANKS, BUT NO THANKS RATHER THAN GET THIS BOARD
7	CAUGHT UP IN ANY KIND OF INTERNAL CONTROVERSY OR
8	INTERNAL YOU KNOW, THIS IS AN ISSUE THAT WE DON'T
9	NEED TO ADDRESS, WE HAVE NOT BEEN ASKED TO ADDRESS.
10	AND IT'S REALLY UP TO YOU BECAUSE THEY'VE ASKED YOU
11	FOR YOUR COMMENTS. IF YOU REALLY WANT TO BRING THIS
12	AND MAKE THIS A BIG PART OF WHAT THE BOARD IS GOING
13	TO BE DEALING WITH BECAUSE YOU'RE JUST OPENING UP
14	PANDORA'S BOX.
15	CHAIRMAN KLEIN: LET ME SAY THIS, JEFF.
16	MAYBE WE CAN SEPARATE THIS INTO TWO PARTS TO
17	POTENTIALLY BE RESPONSIVE. BECAUSE THEY'RE GOING TO
18	COME UP WITH THEIR RECOMMENDATIONS. TO THE EXTENT
19	THAT WE TRY AND BE RESPONSIVE, I THINK THERE MIGHT
20	BE A BETTER RECEPTION FOR US. BUT POTENTIALLY THERE
21	ARE TWO POINTS. ONE WE CAN SAY FOR LONG-TERM
22	CHANGES, WE NEED TO GET TO A STUDY PERIOD AND REPORT
23	BACK TO YOU NEXT YEAR. FOR SHORT-TERM CHANGES,
24	DEALING LIKE WITH ALTERNATES FOR THE IF THERE'S A
25	SENSE THAT PATIENT ADVOCATES SHOULD BE ABLE TO HAVE
	40

ON THE SYSTEM, MAYBE WE COULD ADDRESS THOSE ITEMS
IMMEDIATELY AND SAY, YOU KNOW, FOR A MORE IN-DEPTH
ANALYSIS, THESE OTHER ITEMS ARE NOT URGENT, WE'RE
FUNCTIONING WELL, WE PERFORM VERY WELL, WE'VE HAD A
GREAT DEAL OF ACCOMPLISHMENTS.
AND THOSE LONGER IN-DEPTH ITEMS WE CAN
SAY, QUITE PROPERLY, WE NEED QUITE A BIT OF TIME TO
STUDY THEM TO GET BACK TO THEM WITH A THOUGHTFUL
RESPONSE.
SO I THINK WE'VE HAD A REASONABLE
DISCUSSION OF THIS. I'D LIKE TO SEE IF THERE'S ANY
PUBLIC COMMENT, AND THEN WE CAN HAVE SOME CONCLUDING
REMARKS, AND HOPEFULLY ADJOURN BECAUSE IT IS A
FRIDAY AFTERNOON BEFORE CHRISTMAS. I'M TRYING TO BE
SENSITIVE WHILE INTRODUCING THE TOPIC ON THE
SCHEDULE THAT IS CONSISTENT WITH WHAT THE LITTLE
HOOVER COMMISSION WAS LOOKING FOR.
IS THERE ANY PUBLIC COMMENT IN ANY OF THE
OTHER LOCATIONS OTHER THAN SAN FRANCISCO?
DR. PRI ETO: NOT HERE.
CHAIRMAN KLEIN: HEARING NONE, DON REED,
YOU HAVE SOME COMMENTS.
MR. REED: AS SOMEBODY WHO ATTENDED THE
HEARING, I FELT THAT THEY WERE ASKING A COUPLE
49

1	THINGS. THEY WANTED TO KNOW YOUR PERSONAL OPINIONS,
2	BUT ALSO THE KEY THRUST OF THE ATTACKS ON US FROM
3	THE CRITICS WAS JUST THAT THE BOARD IS UNWIELDY AND
4	IT'S NOT VERY EFFICIENT. THEY HAD CRITICAL COMMENTS
5	TO MAKE ABOUT IT.
6	I THINK THAT THERE'S AN IMPORTANT POINT TO
7	BE MADE HERE IS THAT THE BOARD DOES WORK WELL AND
8	GETS THINGS DONE. IT WRESTLES THINGS BACK AND FORTH
9	AND FINDS ANSWERS. AND I THINK THAT THAT IS AN
10	APPROPRIATE RESPONSE. JUST SAY BASICALLY IT'S
11	WORKING. WE'LL ALWAYS FIND WAYS TO IMPROVE IT, BUT
12	IT IS WORKING. I THINK THAT SHOULD BE ONE OF THE
13	POINTS HERE.
14	AS FAR AS LONG-TERM THINGS, WE'RE NOT IN
15	THE LONG TERM. WE'RE JUST BARELY GETTING STARTED.
16	ONLY BEEN WORKING 20 MONTHS. I THINK WE HAVE TO
17	HAVE TIME TEN YEARS FROM NOW, EIGHT YEARS FROM
18	NOW, THAT'S WHEN EVERYBODY SHOULD EVALUATE AND SEE
19	HOW WE'RE DOING. IT'S NOT UP TO US. RIGHT NOW
20	WE'RE JUST DOING WHAT WE SHOULD BE DOING, AND THAT'S
21	WHAT WE SHOULD BE DOING.
22	CHAIRMAN KLEIN: I WOULD ALSO SAY THAT
23	UNDERLYING THE FACT THAT THE BOARD HAS BEEN HIGHLY
24	PRODUCTIVE, STRESS, JEFF, YOUR POINT, THAT RIGHT NOW
25	WE'RE UNDER STRESS OF A LOT OF BUSINESS. AND, YOU

1	KNOW, I THINK THAT THERE COULD BE SUBSTANTIAL MERIT
2	IN THINGS THAT WE DON'T CRITICALLY NEED TO ADDRESS
3	IMMEDIATELY IF THE LITTLE HOOVER COMMISSION IS
4	RESPONSIVE, AND I WOULD INTEND TO MEET WITH THEM AND
5	SEE WHAT THE RESPONSE IS, TO TRY AND ADDRESS THOSE
6	THINGS THAT WE NEED TO ADDRESS IMMEDIATELY, AND HAVE
7	THE LONG-TERM, THOUGHTFUL DISCUSSION, JEFF, THAT YOU
8	SUGGEST IS NECESSARY AND APPROPRIATE WITH PUBLIC
9	COMMENT MAYBE OVER A LONGER PERIOD OF TIME.
10	IS THERE ANY OTHER BOARD COMMENT? I THANK
11	YOU. AND I WOULD SAY THAT WE HAD SOME SEVERE
12	CRITICISM AT THE BEGINNING OF THE LITTLE HOOVER
13	COMMISSION. I HOPE YOU WILL SEE THAT BY THE END OF
14	THE LITTLE HOOVER COMMISSION WE HAD SOME VERY
15	SUPPORTIVE COMMENTS. AND THEN THERE WAS A MEETING
16	AFTER THAT, A WORKING GROUP MEETING OF THE LITTLE
17	HOOVER COMMISSION. AND, DON, YOU WERE AT THAT
18	WORKING GROUP AFTER THE FORMAL HEARING WHERE THE
19	BOARD OPENLY DISCUSSED WITH STAFF WITH THE PUBLIC
20	PRESENT WHAT THEIR FEELINGS WERE.
21	WOULD YOU LIKE TO COMMENT ON THE TENOR OF
22	THAT FOLLOW-UP SESSION?
23	MR. GIBBONS: WELL, I THINK THEY WERE
24	FEELING THAT CIRM WAS PROBABLY DOING ITS JOB. THEY
25	WERE STILL CURIOUS TO SEE IF THERE'S MORE

1	EFFICIENCIES, BUT I THINK THEY WERE EQUALLY CURIOUS
2	TO SEE IF THERE WAS THINGS THAT CIRM WAS DOING RIGHT
3	THAT THEY COULD MAYBE ADOPT TO OTHER STATE AGENCIES.
4	SO I THINK THEY HAD A VERY OPEN MIND AT
5	THE END OF THE HEARING IN TERMS OF, YOU KNOW, CIRM
6	IS GETTING SOME THINGS CLEARLY RIGHT, AND THEY WERE
7	REALLY CURIOUS ABOUT SOME OF THE BOARD ISSUES. BUT
8	I DON'T THINK THEY FELT THAT THEY WERE THINGS THAT
9	WERE DRASTIC OR HAD TO BE CORRECTED NOW. I THINK
10	THEY FELT THAT IN ONE BOARD MEMBER'S COMMENTS, I SAW
11	THE RED FLAGS. SO I THINK THAT WAS THE BOTTOM LINE.
12	CHAIRMAN KLEIN: OKAY. WELL, SO WE THANK
13	YOU VERY MUCH. WE DID TELL LITTLE HOOVER COMMISSION
14	WE WOULD TRY AND INITIATE THIS PROCESS REASONABLY
15	QUICKLY. APPRECIATE ALL OF YOUR COMMENTS AND VIEWS,
16	A LOT OF DIVERGENT VIEWS ON THIS COMMITTEE THAT
17	REPRESENT THE RICHNESS OF IDEAS OF THE BOARD
18	MEMBERS. AND WE WILL ASK THAT, AFTER LOOKING AT THE
19	TESTIMONY, IF INDIVIDUALS COULD SEND WHAT THEY THINK
20	ARE CRITICAL SHORT-TERM ITEMS THAT NEED TO BE
21	ADDRESSED. WE'LL TRY AND FIRST FOCUS ON THOSE GIVEN
22	CRITICAL TIME, THE MOVEMENT OF FEDERAL LEGISLATION
23	THAT IS TERRIBLY IMPORTANT TO US, AND OUR OTHER
24	AGENDA ITEMS. BUT I THANK YOU, AND I WISH ALL OF
25	YOU THE BEST HOLIDAY POSSIBLE AS WE GO FORWARD.
	E 2

```
DR. POMEROY: HAVE A GOOD HOLIDAY, BOB.
 1
 2
                MR. GOLDBERG: THANK YOU, BOB.
                DR. PRI ETO: THANK YOU, BOB.
 3
                MR. SHEEHY: THANK YOU, BOB.
 4
                      (THE MEETING WAS THEN CONCLUDED AT
 5
      04: 22 P.M.)
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                 53
```

### REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE LEGISLATIVE SUBCOMMITTEE TO THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON FRIDAY, DECEMBER 19, 2008, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152

BARRISTER'S REPORTING SERVICE

1072 BRI STOL STREET

SUITE 100

COSTA MESA, CALIFORNIA

(714) 444-4100